Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. Issue 2 (21st September 2020)
- Record Type:
- Journal Article
- Title:
- Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. Issue 2 (21st September 2020)
- Main Title:
- Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
- Authors:
- Wang, Yuelong
Deng, Jiaojiao
Wang, Lin
Zhou, Tingyue
Yang, Jinlong
Tian, Zerong
Yang, Jinhao
Chen, Hongxu
Tang, Xin
Zhao, Shasha
Zhou, Liangxue
Tong, Aiping
Xu, Jianguo - Abstract:
- Abstract : Background: Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little is known about the expression and clinical significance of B7 family ligands/receptors in CP patients. Thus, we conducted the present study to address this issue in a cohort of 132 CP cases. Methods: We mapped and quantified the expression of B7 family ligands/receptors molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 and V-domain Ig-containing suppressor of T cell activation (VISTA) in 89 adamantinomatous-type CP and 43 papillary-type CP samples using immunohistochemistry and immunofluorescence. Associations between the marker levels, clinicopathological variables and survival were evaluated. Results: The positive rates of PD-L1, B7-H3, B7-H4 and VISTA in the cohort of 132 CP cases were 76.5%, 100%, 40.2% and 80.3%, respectively. The cut-off values of PD-L1, B7-H3, B7-H4 and PD-L1 expression were determined by survival receiver operating characteristic (ROC) package, which was 70, 182, 0 and 20, respectively. Elevated expressions of PD-L1, B7-H3, B7-H4 and VISTA were significantly associated with some clinicopathological characteristics. Kaplan-Meier analysis indicated that higher VISTA expressions correlated with better overall survival (OS) and progression-free survival (PFS) (p=0.0053 and p=0.0066, respectively). Multivariate Cox regression analysis indicated that VISTA was an independent prognostic factor for OS (p=0.018) but not forAbstract : Background: Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little is known about the expression and clinical significance of B7 family ligands/receptors in CP patients. Thus, we conducted the present study to address this issue in a cohort of 132 CP cases. Methods: We mapped and quantified the expression of B7 family ligands/receptors molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 and V-domain Ig-containing suppressor of T cell activation (VISTA) in 89 adamantinomatous-type CP and 43 papillary-type CP samples using immunohistochemistry and immunofluorescence. Associations between the marker levels, clinicopathological variables and survival were evaluated. Results: The positive rates of PD-L1, B7-H3, B7-H4 and VISTA in the cohort of 132 CP cases were 76.5%, 100%, 40.2% and 80.3%, respectively. The cut-off values of PD-L1, B7-H3, B7-H4 and PD-L1 expression were determined by survival receiver operating characteristic (ROC) package, which was 70, 182, 0 and 20, respectively. Elevated expressions of PD-L1, B7-H3, B7-H4 and VISTA were significantly associated with some clinicopathological characteristics. Kaplan-Meier analysis indicated that higher VISTA expressions correlated with better overall survival (OS) and progression-free survival (PFS) (p=0.0053 and p=0.0066, respectively). Multivariate Cox regression analysis indicated that VISTA was an independent prognostic factor for OS (p=0.018) but not for PFS (p=0.898). Conclusions: We found variable expression of PD-L1, B7-H3, B7-H4 and VISTA proteins in CPs. The results suggest that the expression level of VISTA may be used as an important indicator to predict the OS and PFS of CPs. B7 family ligands/receptors could be potential immunotherapeutic targets when treating CPs. … (more)
- Is Part Of:
- Journal for immunotherapy of cancer. Volume 8:Issue 2(2020)
- Journal:
- Journal for immunotherapy of cancer
- Issue:
- Volume 8:Issue 2(2020)
- Issue Display:
- Volume 8, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 8
- Issue:
- 2
- Issue Sort Value:
- 2020-0008-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-09-21
- Subjects:
- tumours -- pathology
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105 - Journal URLs:
- http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1136/jitc-2019-000406 ↗
- Languages:
- English
- ISSNs:
- 2051-1426
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23781.xml